Get the Stockscreener App
17.08
1.67%
-0.29
After Hours:
17.08
Eyepoint Inc stock is traded at $17.08, with a volume of 737.49K.
It is down -1.67% in the last 24 hours and down -4.15% over the past month.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
See More
Previous Close:
$17.37
Open:
$17.5
24h Volume:
737.49K
Relative Volume:
0.58
Market Cap:
$1.41B
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-9.3846
EPS:
-1.82
Net Cash Flow:
$-1.61M
1W Performance:
-6.51%
1M Performance:
-4.15%
6M Performance:
+71.66%
1Y Performance:
+87.49%
1-Day Range:
$16.94
$17.74
1-Week Range:
$16.67
$18.50
52-Week Range:
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Name
Eyepoint Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
17.08 | 1.44B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Inc Stock (EYPT) Latest News
Is EyePoint Pharmaceuticals Inc. stock affected by interest rate hikes2025 Year in Review & Safe Investment Capital Preservation Plans - ulpravda.ru
How sustainable is EyePoint Pharmaceuticals Inc. stock dividend payoutJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - ulpravda.ru
Will EyePoint Pharmaceuticals Inc. stock continue dividend increasesMarket Volume Report & Entry Point Confirmation Alerts - ulpravda.ru
Will EyePoint Pharmaceuticals Inc. stock remain a Wall Street favoriteWeekly Profit Summary & Long-Term Capital Growth Ideas - ulpravda.ru
Eyepoint Insider Sold Shares Worth $727,319, According to a Recent SEC Filing - MarketScreener
Mizuho reiterates Outperform rating on EyePoint stock with $33 target - Investing.com
RBC Capital reiterates Outperform rating on EyePoint stock at $39 target - Investing.com Nigeria
Mizuho reiterates Outperform rating on EyePoint stock with $33 target By Investing.com - Investing.com India
EyePoint’s Phase 3 trials for DURAVYU in wet AMD on track for mid-2026 data - Investing.com
EyePoint, Inc. Advances DURAVYU in Pivotal Phase 3 Trials for Wet AMD and DME with Key Milestones Expected in 2026 - Quiver Quantitative
Uveitis Treatment Market to Reach US$ 1,258.35million | CAGR - openPR.com
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 - GlobeNewswire Inc.
Can EyePoint Pharmaceuticals Inc. stock maintain growth trajectory2026 world cup usa national team group stage star players transition play group prediction guide - ulpravda.ru
Is EyePoint Pharmaceuticals the Next Sleeper Stock Legend or Just Overhyped Noise? - AD HOC NEWS
Institutional Investors in EyePoint, Inc. (NASDAQ:EYPT) See US$67m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them. - 富途牛牛
EyePoint (EYPT) price target increased by 10.87% to 36.80 - MSN
What drives EyePoint Pharmaceuticals Inc PV3B stock priceSell Signals and Alerts & Top Analyst Picks Available for Free - earlytimes.in
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.1%Here's What Happened - MarketBeat
The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga
Understanding the Setup: (EYPT) and Scalable Risk - Stock Traders Daily
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
EyePoint, Inc.Common Stock (Nasdaq:EYPT) Stock Quote - FinancialContent
127,489 Shares in Eyepoint Pharmaceuticals, Inc. $EYPT Purchased by Corient Private Wealth LLC - MarketBeat
Why EyePoint (EYPT) Is Up 9.6% After Upbeat Earnings Revisions And Momentum SignalsAnd What's Next - Sahm
EyePoint (EYPT): Assessing Valuation After Earnings Upgrades and Strong Momentum-Driven Share Gains - Yahoo Finance
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 6.2%Time to Sell? - MarketBeat
EyePoint Earnings Notes - Trefis
EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know - Yahoo Finance
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 - Zacks Investment Research
Would You Still Hold EyePoint Stock If It Fell 30%? - Trefis
Will EyePoint Pharmaceuticals Inc. stock rally after Fed decisionsWeekly Risk Summary & Technical Analysis for Trade Confirmation - Улправда
EyePoint (EYPT) Price Target Increased by 10.87% to 36.80 - Nasdaq
Is EyePoint Pharmaceuticals Inc. stock dividend yield sustainable2025 Technical Overview & Expert Approved Momentum Ideas - Улправда
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Rating Increased to Strong-Buy at TD Cowen - MarketBeat
Why (EYPT) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside - Barchart.com
Can EyePoint Pharmaceuticals Inc. stock resist market sell offsMarket Risk Summary & High Conviction Buy Zone Picks - Улправда
Is EyePoint Pharmaceuticals Inc a good long term investmentOptions Trading Strategies & Free Tap Rapid Wealth - earlytimes.in
Is EyePoint Pharmaceuticals Inc. stock overvalued by current metricsPortfolio Value Report & Weekly High Conviction Trade Ideas - Улправда
Will EyePoint Pharmaceuticals Inc. stock reach all time highs in 2025 - DonanımHaber
Inflation Data: How EyePoint Pharmaceuticals Inc. (PV3B) stock compares with market leadersJuly 2025 Sentiment & Community Trade Idea Sharing Platform - Улправда
How EyePoint Pharmaceuticals Inc. stock reacts to oil pricesWeekly Stock Recap & Expert Approved Trade Ideas - DonanımHaber
Should I hold or sell EyePoint Pharmaceuticals Inc. stock in 2025July 2025 Rallies & Low Risk Growth Stock Ideas - Улправда
Support Test: Will EyePoint Pharmaceuticals Inc. stock see PE expansionDividend Hike & Low Risk Entry Point Guides - Улправда
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Globe and Mail
EyePoint, Inc. CEO Jay S. Duker to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Eye disease drug developer to present at major healthcare conf - Stock Titan
EyePoint (STU:PV3B) OCF Margin % : -6,144.59% (As of Sep. 2025) - GuruFocus
EyePoint reports inducement grants under NASDAQ listing rule - MSN
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading 5.8% HigherWhat's Next? - MarketBeat
EyePoint (EYPT) Grants Stock Options to New Employees as Inducem - GuruFocus
Eyepoint Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
4.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):